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Background: Steroid-resistant nephrotic syndrome (SRNS) is an important cause of
chronic kidney disease (CKD) in children that often progresses to end-stage renal disease
(ESRD). Calcineurin inhibitors (CNIs) have been shown to be effective in inducing short-
term remission in some patients with SRNS. However, there are little data examining their
long-term impact on ESRD progression rates.
Methods:We performed a retrospective chart review of all patients treated for SRNS with
CNIs at our institution from 1995 to 2013. Data collected including demographics, initial
response to medical therapy, number of relapses, progression to ESRD, and treatment
complications.
Results: A total of 16 patients met inclusion criteria with a mean follow-up of 6.6 years
(range 0.6–17.6 years). Histopathological diagnoses were focal segmental glomeruloscle-
rosis (8), mesangial proliferative glomerulonephritis (4), IgM nephropathy (3), and minimal
change disease (1). Three patients (18.8%) were unresponsive to CNIs while the remaining
13 (81.2%) achieved remission with CNI therapy. Six patients (37.5%) progressed to
ESRD during the study period, three of whom did so after initially responding to CNI
therapy. Renal survival rates were 87, 71, and 57% at 2, 5, and 10 years, respectively.
Non-Caucasian ethnicity was associated with progression to ESRD. Finally, a higher
number of acute kidney injury (AKI) episodes were associated with a lower final estimated
glomerular filtration rate.
Discussion: Despite the majority of SRNS patients initially responding to CNI therapy, a
significant percentage still progressed to ESRD despite achieving short-term remission.
Recurrent episodes of AKI may be associated with progression of CKD in patients with
SRNS.
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INTRODUCTION
Nephrotic syndrome is a rare clinical syndrome consisting of
high grade proteinuria, hyperlipidemia, hypoalbuminemia, and
edema. Nephrotic syndrome affects ~2–7 children per 100,000
and affects all ages and ethnic backgrounds (1–4). Prior stud-
ies have demonstrated that ~80% of children diagnosed with
nephrotic syndrome will respond to steroid therapy (5). However,
there is recent evidence that the incidence of initial steroid resis-
tance is increasing (6). Previous long-term follow-up studies have
demonstrated favorable prognosis if remission is achieved with
steroids (7, 8).
The majority of patients with steroid-resistant nephrotic syn-
drome (SRNS) will have focal segmental glomerulosclerosis
(FSGS) found on biopsy (2, 5). Historical studies examining SRNS,
specifically caused by FSGS, provided evidence that >50% of
children who do not respond to initial steroid therapy would
progress to end-stage renal disease (ESRD) within 3 years (9, 10).
Due to the unfavorable prognosis of SRNS, numerous therapies
have been utilized in an attempt to achieve remission, including
cyclosporine, tacrolimus, cyclophosphamide, and rituximab. The
most predominant therapies utilized are the calcineurin inhibitors
(CNIs), cyclosporine, and/or tacrolimus, which are the current
recommended first line therapy for SRNS per the 2012 Kidney
Diseases Improving Global Outcomes (KDIGO) Guidelines (11).
Numerous studies have demonstrated their efficacy in achieving
short-term remission (12–14). While several studies have exam-
ined long-term outcomes in SRNS (15–18), there aremany limita-
tions to these results. The goal of the current study was to examine
the long-term (>5 years) follow-up of SRNS patients treated with
CNIs at a single institution, with specific attention paid to those
who initially showed good response to CNIs.
MATERIALS AND METHODS
A retrospective chart review was performed of all patients with
SRNS treated with CNIs from January 1995 through August 2013
at Rainbow Babies and Children’s Hospital. Patients were iden-
tified via ICD-9 billing code search. Inclusion criteria were (1)
diagnosis of SRNS, with a minimum of 6months follow-up from
initial diagnosis; (2) age 1–18 years at the time of diagnosis; and (3)
treatmentwith either cyclosporineA and/or tacrolimus. Exclusion
criteria were (1) steroid dependent and/or frequently relapsing
NS, (2) late-onset steroid resistance, or (3) incomplete medical
records. Definitions of steroid response, remission, and relapse
were based upon the 2012 KDIGO guidelines (11).
Data Collection
Data collected from themedical records of childrenmeeting inclu-
sion criteria included basic demographic data (age, gender, and
race), clinical features at diagnosis (presence of hematuria, hyper-
tension, serum creatinine, and urine protein/creatinine ratio),
histopathology, and growth parameters (weight and height). Lon-
gitudinal follow-up data were also collected and included num-
ber of relapses/remissions, complications of disease/treatment
[infections requiring hospital admission, development of diabetes
mellitus, development of hypertension, thrombosis/stroke, and
episodes of acute kidney injury (AKI)], and estimated GFR
(eGFR). AKI was defined as a 0.3mg/dL rise in the serum
creatinine within a 48-h period per the AKI network criteria (19).
eGFR was calculated using the original bedside Schwartz equa-
tion and the modified Schwartz equation when serum creatinine
was measured using isotope dilution mass spectrometry (IDMS)
(20, 21). End follow-up occurred at the completion of the study
period or when the patient progressed to ESRD (transplantation
or dialysis).
Statistical Analysis
Baseline results were expressed as means with ranges and per-
centages. Given the small patient sample size normality was not
assumed and all statistics were performed non-parametrically.
Due to the small sample size, all patients were included in the final
statistical analysis regardless of their initial response to calcineurin
inhibition. Statistical tests utilized include Pearson chi-squared,
Mann–WhitneyU test, Pearson correlation, Spearman rank corre-
lation, and Kaplan–Meier survival analysis. All statistical analyses
were performed with the SPSS software suite (version 22.0). The
research design and statistical analysis was approved byUniversity
Hospitals/Case Western Reserve University Institutional Review
Board.
RESULTS
A total of 34 patients were identified of which 16 met all inclu-
sion criteria. Of the 18 excluded patients, 14 had either late-
onset steroid resistance or steroid dependence, 2 patients were
not treated with CNIs, and 2 patients’ records were unavailable.
Mean age at onset of SRNS was 6.9 years (1.7–13 years) and mean
duration of follow-up was 6.6 years (range 0.6–17.6 years). Seven
of the 16 children were male (43.8%). Nine of the children were
African-American (56.2%), four children were Caucasian (25%),
and three children were Hispanic (18.8%). All patients underwent
biopsy soon after diagnosis of SRNS with eight patients having
focal segmental glomerular sclerosis (50%), four with mesangial
proliferative glomerulonephritis (25%), three with IgMnephropa-
thy (18.8%), and one patient with minimal change disease (6.2%).
The majority of patients were treated with cyclosporine A (10
patients, 62.5%) with only 2 patients (12.5%) receiving tacrolimus,
whereas 4 patients (25%) were treated with both medications
during the study period. Demographic and clinical features of the
study cohort are summarized in Table 1.
Thirteen of the 16 patients (81.3%) achieved remission with
CNI therapy. The three patients who failed to achieve ini-
tial remission all progressed to ESRD during the length of
follow-up (7, 11months, and ~5 years). Among patients achiev-
ing initial remission, relapses were common with a mean of
3.4 relapses (0.5 relapses/year). Complications that arose during
the course of treatment included infections requiring admis-
sion (three patients), steroid-induced cataracts (one patient),
venous/arterial thrombosis (three patients), and one patient who
suffered posterior reversible encephalopathy syndrome. AKI was
also very common with 13/16 patients (81.3%) having at least
one episode of AKI. The mean number of AKI episodes was
2.1 1.5 among all 16 patients in the study, which corresponds to
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TABLE 1 | Study population baseline characteristics.
Gender Male: 7 (44%)
Female: 9 (56%)
Mean age at onset (years) 6.9 (1.7–13.9)
Histopathology FSGS: 8 (50%)
MPGN: 4 (25%)
IgM nephropathy: 3 (19%)
Minimal change: 1 (6%)
Ethnicity African-American: 9 (56%)
Caucasian: 4 (25%)
Hispanic: 3 (19%)
Medication Cyclosporine A: 10 (63%)
Tacrolimus: 2 (12%)
Both: 4 (25%)
a mean 0.7 1.1 AKI episode per patient year of follow-up.When
restricted to only those patients achieving remission with CNI
therapy (n= 13) the mean number of AKI episodes per patient
year was 0.34 0.3 episodes. Reversibility to baseline creatinine
was seen in 71%ofAKI episodeswith the remaining 29% adopting
a new baseline.
A total of 6 out of 16 patients (37.5%) developed ESRD during
the study period: 3/3 (100%) of CNI non-responders and 3/13
(23%) of CNI responders. Table 2 summarizes the demographic
and clinical features results based on renal outcome (ESRD vs.
non-ESRD). The only two significant associations with ESRD in
the study population were non-Caucasian race (p= 0.024), and
the mean number of AKI episodes per patient year of follow-
up (p= 0.031). No other significant associations with ESRD were
identified in the study population with respect to age, gender,
histopathology, medication, or number of remissions. Finally,
eGFR was inversely associated with a higher mean number of
AKI episodes (p= 0.022, 95% confidence interval= 28.5 to
 2.5mL/min/1.73m2). No other associations with lower final
eGFR were identified. Kaplan–Meier renal survival analysis was
performed and demonstrated survival rates of 87, 71, and 57% at
2, 5, and 10 years, respectively (see Figure 1). When CNI non-
responders were eliminated from the statistical analysis, the only
significant correlationwasAKI episodes per patient year of follow-
up with lower eGFR (p= 0.03). Kaplan–Meier renal survival anal-
ysis for CNI responders demonstrated renal survival rates of 88,
80, and 57% at 2, 5, and 10 years, respectively (see Figure 2).
DISCUSSION
Steroid-resistant nephrotic syndrome remains a challenging clin-
ical entity and many patients still struggle to achieve remission
despite newer therapies. Failure to achieve remission with steroids
was historically associated with rates of progression to ESRD
>50% within a 5-year period (9, 10). Since the advent of CNIs
(and other therapies), there has been a paucity of long-term out-
come data regarding progression to ESRD. This study provides
further evidence regarding the long-term outcomes of SRNS. A
significant percentage (18.8%) failed to respond to CNIs, all of
whom progressed to ESRD. Among those initially responding
to CNIs, 23% (3/13) still progressed to ESRD. Although renal
TABLE 2 | Study demographics and results by renal outcome.
Non-ESRD (n=10) ESRD (n=6) p-Value
Gender (% male) 4 (40%) 3 (50%) 0.696
Mean age at onset
(years)
6.1 (1.7–13.2) 8.5 (1.7–13.9) 0.301
Histopathology FSGS: 5 (50%) FSGS: 3 (50%) 0.828
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Mean number of AKI
episodes
1.5 3.3 0.073




Red bold text indicates statistical significance.
FIGURE 1 | Kaplan–Meier renal survival curve for all subjects. Vertical
dashed lines represent time points of 2, 5, and 10 years for both CNI
responders and CNI non-responders.
survival at 1 and 5 years was still fairly good (>80%), the 10-year
renal survival of that group was 57%, demonstrating the impor-
tance of following these long-term clinical course.
A growing body of evidence in adult nephrology literature
that suggests the recurrent episodes of AKI may be associated
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FIGURE 2 | Kaplan–Meier renal survival curve for calcineurin inhibitor
responders. Vertical dashed lines represent time points of 2, 5, and 10 years
for subjects who initially responded to CNI inhibitors.
with worse chronic kidney disease (CKD) (22–24). Several studies
in pediatric ICU settings have demonstrated development of
CKD after AKI in pediatric patients (25, 26). Given that patients
with SRNS treated with CNIs, which may also be treated with
angiotensin converting enzyme inhibitors or angiotensin receptor
blockers, we hypothesized that this population is at high risk for
developing AKI.
Our study did, in fact, confirm that AKI is a common occur-
rence among SRNS patients, with more than 80% of patients
suffering an episode of AKI during their follow-up period and
most patients havingmore than one episode ofAKI. Exact etiology
of these AKI episodes could not be determined retrospectively;
however, the majority of AKI episodes occurred during time
of relapse. Prior studies examining complications of nephrotic
syndrome (not specifically SRNS) demonstrate that ~10% of all
admissions for nephrotic syndrome are associated with AKI (27).
Furthermore, we identified a significant association between AKI
episodes and progression to ESRD. We hypothesize that these
episodes of AKI lead to cumulative damage that increases the
risk of progression to ESRD. This finding highlights the impor-
tance of rapidly identifying and managing even mild AKI in this
population.
Several other studies have examined the outcome of SRNS
but with important limitations. Otukesh et al. (15) examined
59 children with early steroid resistance and found a renal sur-
vival rate of 56% at 10 years; however, the study included both
early and late steroid resistance and therapy with cyclophos-
phamide and mycophenolate mofetil in addition to cyclosporine
A. Gellermann et al. (28) demonstrated effectiveness in achieving
sustained remission using a combination of cyclosporine and
mycophenolate mofetil in early SRNS secondary to FSGS with
a 100% renal survival rate in their cohort. However, the study
only included Caucasian children and at enrollment all patients
were in remission via standard steroids, high dose methyl-
prednisolone addition of cyclosporine if proteinuria did not
improve. It is unclear how many of the given patients may have
responded to the high dose steroids without the addition of
cyclosporine and the inclusion of only a single ethnicity makes it
difficult to extrapolate the results to other populations. Similarly,
Hamasaki et al. (18) performed a prospective 5-year study exam-
ining SRNS and cyclosporine and found a renal survival rate of
94.3%. However, their study also was of a single ethnicity and the
majority of the enrolled patients hadminimal change disease with
only 20% having FSGS. In addition, the shorter follow-up time
compared to our study could have precluded identifying children
who would still enter ESRD but at a later timepoint. Finally, in
the largest series published to date, Zagury et al. (17) examined
the outcomes of SRNS in their population within Brazil of 114
patients with early steroid resistance treated with cyclosporine A.
They found a renal survival rate of 58.4% at 10 years and identified
FSGS and cyclosporine resistance as predictors of progression to
ESRD. These study, however, did not examine episodes of AKI.
As with several of the published studies, our study had impor-
tant limitations, including its retrospective, single center nature,
and the small sample size. In addition, the majority of our
patients in this study were treated with cyclosporine A, so data on
tacrolimus were limited. Target CNI levels varied throughout the
study follow-up period at the discretion of the treating physician.
Trough levels were examined; however, they were highly variable
due to numerous factors including improperly timed collection,
patient non-compliance, and impact of illness. Due to this varia-
tion analysis of the impact of CNI trough levels was unable to be
performed. Finally, although we identified an association between
AKI and progression to ESRD, it is possible that the increased
number of AKI episodes may reflect more severe baseline disease
that would be more likely to progress to ESRD, rather than being
a causative factor of ESRD. Severity of baseline disease could be
further assessed by FSGShistopathology; however, these datawere
unavailable in our study due to many biopsies occurring prior
to the development of the classification scheme used to identify
FSGS histological variants. Further studies examining the role of
FSGS histopathology, AKI, and CKD progression are needed to
address this concern.
In conclusion, this study demonstrates that treatment with
CNIs can be effective in achieving sustained remission for idio-
pathic SRNS. Although short-term prognosis (<5 years) was gen-
erally good, our study found that long-term renal survival was
less favorable, with 43% of CNI-responsive patients progressing
to ESRD at 10 years. These findings are consistent with previ-
ously published data, which suggest that, although newer ther-
apies are slowing the rate of progression, close to 50% will still
reach ESRD during childhood/early adulthood (16–18). Notably,
our study found that increased episodes of AKI were associated
with increased risk of ESRD. While we were unable to establish
causality, these findings provide, for the first time, support for a
relationship between repeated AKI and progression to ESRD in
SRNSA larger, multi-center prospective study would be necessary
to further define long-term outcomes of a diverse population of
children with SRNS responsive to CNIs to and determine the role,
if any, that episodes of AKI may play in the progression to ESRD.
The possibility of long-term adverse effects of AKI episodes in
patients with SRNS emphasizes the importance of AKI prevention
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in this population. Future treatment guidelines should stress the
importance of AKI prevention through avoidance of dehydration,
nephrotoxic medications, and prompt treatment of infections and
relapse episodes.
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